Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by Se
Go back to Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by Se| (NASDAQ: SRRK) | Delayed: 54.62 -2.8 (4.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.42 | 52 Week High | $ | |||
| Open | $57.30 | 52 Week Low | $ | |||
| Day High | $57.65 | P/E | N/A | |||
| Day Low | $54.44 | EPS | $ | |||
| Volume | 1,601,823 | |||||
